Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 361 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Tumor markers Clear all

Conditions: Metastatic Spine Tumor
Interventions: Not listed
Lead sponsor: AO Innovation Translation Center; Other
Eligibility: 18 Years and older
Enrollment: 2,417 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 10
States / cities: San Francisco, California • Chicago, Illinois • Baltimore, Maryland + 7 more

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: UConn Health; Other
Eligibility: 40 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Neoplasms, HPV-Related Anal Squamous Cell Carcinoma
Interventions: HRA + Biopsy, Anal Cytology, Genotyping of anal hrHPV infection, CINtec®PLUS; Diagnostic Test
Lead sponsor: Lisa Flowers; Other
Eligibility: 30 Years to 80 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 4
States / cities: Miami, Florida • Atlanta, Georgia

Conditions: Breast Cancer, Sleep
Interventions: GO! To Sleep, Sleep information, Blood Draw, Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), SF-12 quality of life survey; Behavioral · Procedure · Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 21 Years and older · Female only
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Breast Cancer
Interventions: immunoenzyme technique, laboratory biomarker analysis; Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hemophagocytic Lymphohistiocytosis
Interventions: Blood Draws, Data Collection; Other
Lead sponsor: Swedish Orphan Biovitrum; Industry
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Ovarian Cancer, Peritoneal Cavity Cancer
Interventions: Microarray analysis, Laboratory biomarker analysis; Genetic · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Ovarian Cancer
Interventions: Second Look Laparoscopy; Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Gastroesophageal Adenocarcinoma
Interventions: FLOT, FOLFOX, FOLFIRI, FOLFIRINOX, PACLITAXEL with or without CARBOPLATIN, DOCETAXEL and IRINOTECAN (alone or combined), NIVOLUMAB (alone or when added to a regimen above), PEMBROLIZUMAB (alone or when added to a regimen above), Durvalumab, Trastuzumab; Combination Product · Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Orange, California

Conditions: Cancer
Interventions: Oral cytobrushing; Procedure
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Liver Cirrhosis, Liver Cancer, HCC, Hepatocellular Carcinoma
Interventions: Multi-analyte Blood Test; Diagnostic Test
Lead sponsor: Helio Genomics; Industry
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Timeline: 2022 – 2028
U.S. locations: 7
States / cities: Escondido, California • Mission Hills, California • Gainesville, Florida + 4 more

Conditions: Breast Neoplasms
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2012
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Cancer
Interventions: AMP-224; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 4
States / cities: Detroit, Michigan • New York, New York • Huntersville, North Carolina + 1 more

Conditions: Breast Cancer, Gastrointestinal Cancer, Genitourinary Cancer, Sarcoma, Gynecologic Cancer
Interventions: Doxorubicin, Sildenafil; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Prostate Cancer
Interventions: Computed Tomography (CT) Scan; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Ovarian Cancer
Interventions: Fourier transform ion cyclotron resonance mass spectrometry, chromatography, diagnostic laboratory biomarker analysis, questionnaire administration; Other
Lead sponsor: Pine Street Foundation; Other
Eligibility: 21 Years to 120 Years · Female only
Enrollment: 109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2012
U.S. locations: 4
States / cities: San Anselmo, California • San Francisco, California • Orono, Maine

Conditions: Brain Cancer
Interventions: cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 3 Years to 21 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 11
States / cities: Phoenix, Arizona • Denver, Colorado • Gainesville, Florida + 8 more

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Central Nervous System Neoplasm, Ewing Sarcoma, Germ Cell Tumor, Leukemia, Lymphoma, Malignant Neoplasm, Neuroblastoma, Osteosarcoma, Retinoblastoma, Rhabdoid Tumor, Rhabdomyosarcoma, Soft Tissue Sarcoma
Interventions: Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis; Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2025
U.S. locations: 65
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 46 more

Conditions: Colorectal Neoplasm
Interventions: 2-Fluoro-2-deoxyglucose; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Colon Cancer
Interventions: Stool DNA Test, biopsies of rectal and colon mucosa, Questionnaires; Other · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 30 Years to 80 Years
Enrollment: 3,315 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Metastatic Biliary Tract Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Digestive System Neoplasm, Metastatic Pancreatic Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Interventions: Fluorouracil, Irinotecan Sucrosofate, Laboratory Biomarker Analysis, Leucovorin Calcium, Rucaparib; Drug · Other
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 3
States / cities: Scottsdale, Arizona • Atlanta, Georgia • Rochester, Minnesota

Conditions: Breast Cancer
Interventions: Biomarkers; Other
Lead sponsor: Sentara Norfolk General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 2
States / cities: Newport News, Virginia • Norfolk, Virginia

Conditions: Lung Cancer
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: 50 Years and older
Enrollment: 3,606 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: HER2-positive Breast Cancer
Interventions: RNA sequencing, Transcriptome analysis, Trastuzumab, Chemotherapy; Other · Drug
Lead sponsor: OmicsWay Corp.; Industry
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 40 participants
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Walnut, California

Search by objective public record fields.

Metastatic Tumor Research and Outcomes Network

Anastrozole and Letrozole

Screening Strategies Among High-risk Populations for Anal Cancer

A Sleep Intervention to Improve Outcomes Among Women at High Risk of Breast Cancer

Study of Calgranulin A/B Levels in Patients With Newly Diagnosed Stage I,II,III Breast Cancer

Evaluation of IFNγ and Inflammatory Mediators in Patients With Malignancy-Associated Hemophagocytic Lymphohistiocytosis

Identifying Genetic Markers That Predict Response to Paclitaxel in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer

A Study of Second Look Laparoscopy (SLL) in People With Ovarian Cancer Who Have Completed Their First Course of Chemotherapy

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

Chemical and Genetic Effects of the Experimental Anti-Cancer Drugs in Cheek Cells in Cancer Patients

Multi-analyte Blood Test Clinical Trial

Inflammatory Breast Cancer, Tumor Markers, and Factors Associated With Angiogenesis

Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced Cancer

Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers

Evaluation of Intraprostatic Fiducial Markers For External Beam Radiation Therapy

Early Detection of Ovarian Cancer: GC/FT-ICR Mass Spectrometry and Canine Olfaction

External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas

Collecting and Storing Tissue From Young Patients With Cancer

Phase II Study of the Role of Anti-CEA Antibody Immunoscintigraphy & Positron Emission Tomography in the Localization of Recurrent Colorectal Carcinoma in Patients With Rising Serum CEA Levels in the Absence of Imageable Disease by Conventional Modalities

Screening and Risk Factors of Colon Neoplasia

Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer

Early Detection of Breast Cancer in Women With Suspicious Mammograms

Lung Cancer Biomarkers and Screening

Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer